Medicale Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Medicale Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Sep 30, 2022 | $0 | Dec 2, 2022 |
| FY2022 | Sep 30, 2021 | $0 | Dec 2, 2022 |
| FY2021 | Sep 30, 2020 | $0 | Dec 15, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($41.2K) | Jan 12, 2026 |
| FY2025 | Sep 30, 2024 | ($58.2K) | Jan 12, 2026 |
| FY2024 | Sep 30, 2023 | ($37.1K) | Jan 14, 2025 |
| FY2023 | Sep 30, 2022 | ($46.4K) | Jan 2, 2024 |
| FY2022 | Sep 30, 2021 | ($32.2K) | Dec 2, 2022 |
| FY2021 | Sep 30, 2020 | ($1.9K) | Dec 15, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($33.5K) | Jan 12, 2026 |
| FY2025 | Sep 30, 2024 | ($54.7K) | Jan 12, 2026 |
| FY2024 | Sep 30, 2023 | ($37.6K) | Jan 14, 2025 |
| FY2023 | Sep 30, 2022 | ($44.0K) | Jan 2, 2024 |
| FY2022 | Sep 30, 2021 | ($32.2K) | Dec 2, 2022 |
| FY2021 | Sep 30, 2020 | ($1.9K) | Dec 15, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($23.0K) | Jan 12, 2026 |
| FY2025 | Sep 30, 2024 | ($83.6K) | Jan 12, 2026 |
| FY2024 | Sep 30, 2023 | ($25.7K) | Jan 14, 2025 |
| FY2023 | Sep 30, 2022 | ($24.6K) | Jan 2, 2024 |
| FY2022 | Sep 30, 2021 | ($17.8K) | Dec 2, 2022 |
| FY2021 | Sep 30, 2020 | ($1.1K) | Dec 15, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $0 | Jan 12, 2026 |
| FY2025 | Sep 30, 2024 | $159 | Jan 12, 2026 |
| FY2024 | Sep 30, 2023 | $159 | Jan 14, 2025 |
| FY2023 | Sep 30, 2022 | $0 | Jan 2, 2024 |
| FY2022 | Sep 30, 2021 | $28.3K | Dec 2, 2022 |
| FY2021 | Sep 30, 2020 | $12.2K | Dec 15, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $140.1K | Jan 12, 2026 |
| FY2025 | Sep 30, 2024 | $99.1K | Jan 12, 2026 |
| FY2024 | Sep 30, 2023 | $40.9K | Jan 14, 2025 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($140.1K) | Jan 12, 2026 |
| FY2025 | Sep 30, 2024 | ($98.9K) | Jan 12, 2026 |
| FY2025 | Sep 30, 2023 | ($40.7K) | Jan 12, 2026 |
| FY2024 | Sep 30, 2022 | ($54.8K) | Jan 14, 2025 |
| FY2023 | Sep 30, 2021 | ($8.4K) | Jan 2, 2024 |
| FY2022 | Sep 30, 2020 | ($1.4K) | Dec 2, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($217.0K) | Jan 12, 2026 |
| FY2025 | Sep 30, 2024 | ($175.8K) | Jan 12, 2026 |
| FY2024 | Sep 30, 2023 | ($117.6K) | Jan 14, 2025 |
| FY2023 | Sep 30, 2022 | ($80.5K) | Jan 2, 2024 |
| FY2022 | Sep 30, 2021 | ($34.1K) | Dec 2, 2022 |
| FY2021 | Sep 30, 2020 | ($1.9K) | Dec 15, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Sep 30, 2021 | $18.5K | Dec 15, 2021 |
| FY2021 | Sep 30, 2020 | $0 | Dec 15, 2021 |
| FY2021 | Aug 16, 2020 | $0 | Dec 15, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Jan 12, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Jan 12, 2026 |
| FY2024 | Sep 30, 2023 | 0 | Jan 14, 2025 |
| FY2023 | Sep 30, 2022 | 0 | Jan 2, 2024 |
| FY2022 | Sep 30, 2021 | 0 | Dec 2, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Jan 12, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Jan 12, 2026 |
| FY2024 | Sep 30, 2023 | 0 | Jan 14, 2025 |
| FY2023 | Sep 30, 2022 | 0 | Jan 2, 2024 |
| FY2022 | Sep 30, 2021 | 0 | Dec 2, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 5.92M | Jan 12, 2026 |
| FY2025 | Sep 30, 2024 | 5.92M | Jan 12, 2026 |
| FY2024 | Sep 30, 2023 | 5.92M | Jan 14, 2025 |
| FY2023 | Sep 30, 2022 | 5.92M | Jan 2, 2024 |
| FY2022 | Sep 30, 2021 | 5.92M | Dec 2, 2022 |
| FY2021 | Sep 30, 2020 | 3.40M | Dec 15, 2021 |